
the**bmj** Visual summary

Adverse events: GSK pandemic influenza vaccines

The BMJ gained access to vaccine pharmacovigilance reports compiled by GSK (GlaxoSmithKline) during the 2009 H1N1 "swine flu" outbreak. The reports detail adverse events for three of the company's pandemic influeza vaccines: Pandemrix, Arepanrix, and an H1N1 vaccine without adjuvant (no brand name provided).


Despite similarities in the composition of Pandemrix and Arepanrix vaccines, the rates of adverse events reported differed substantially. Neither GSK nor health authorities seem to have made the information public during the H1N1 outbreak or in the eight years since.


Serious adverse events, including death, are evidently more common with Pandemrix



A continuous pattern

Shown here, data from GSK's "enhanced safety review team reports" for nine time points between 2 December 2009 and 31 March 2010. Over these four months, the doses of Pandemrix administered went from 15 million to 70 million, and the pattern of adverse events continued. The graphs present adverse event reports per million doses of vaccine administered, cumulatively over time.







Read the full article online



© 2018 BMJ Publishing group Ltd.

Disclaimer: This infographic is not a validated clinical deci conditions, or warranties that it is accurate or up to date. BMJ and its licensors assume no responsibility for any aspect of













